Beam Therapeutics (BEAM) Income towards Parent Company (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Income towards Parent Company data on file, last reported at -$98.3 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 10.25% year-over-year to -$98.3 million in Q1 2026; TTM through Mar 2026 was -$52.2 million, a 86.52% increase from a year earlier, with the FY2025 full-year figure at -$63.2 million, up 83.23% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$98.3 million, down from $261.1 million in the prior quarter.
• Over the last five years, Income towards Parent Company for BEAM reached as high as $261.1 million in Q4 2025 and fell as low as -$176.2 million in Q2 2022.
• Historically, Income towards Parent Company has averaged -$61.9 million across 5 years, with a median of -$92.7 million in 2024.
• Across the five-year window, Income towards Parent Company plunged 199.01% in 2022 and jumped 472.27% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$38.3 million in 2022, then soared by 472.27% to $142.8 million in 2023, then sank by 163.29% to -$90.4 million in 2024, then surged by 388.97% to $261.1 million in 2025, then plunged by 137.65% to -$98.3 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$98.3 million in Q1 2026, $261.1 million in Q4 2025, and -$112.7 million in Q3 2025.